2026-04-14T06:51:45Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1799732025-12-05T12:16:44Zcom_2072_1057col_2072_478916col_2072_478917

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study Jantus Lewintre, Eloisa Massutí Sureda, Bartomeu González Larriba, José Luis Rodríguez Abreu, Delvys Juan, Oscar Blasco, Ana Dómine, Manuel Provencio Pulla, Mariano Garde, Javier Álvarez, Rosa Maestu, Inmaculada Pérez de Carrión, Ramón Artal, Ángel Rolfo, Christian Castro Carpeño, Javier de Guillot, Mónica Oramas, Juana Peñas, Ramón de las Ferrera, Lioba Martínez Banaclocha, Natividad Serra, Òlbia Rosell, Rafael Camps, Carlos Càncer de pulmó Vasodilatadors Lung cancer Vasodilators Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy. 2021-09-10T10:08:37Z 2021-09-10T10:08:37Z 2021-07-26 2021-09-10T07:18:10Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2234-943X https://hdl.handle.net/2445/179973 34381717 eng Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.695038 Frontiers in Oncology, 2021, vol. 11 https://doi.org/10.3389/fonc.2021.695038 cc by (c) Jantus Lewintre, Eloisa et al, 2021 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess 11 p. application/pdf Frontiers Media SA Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))